NVCT Nuvectis Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1875558 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.8%
TTM EPS YoY-46.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.0%
ROA-57.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $18.15M | $12.92M |
| SG&A expense | $9.42M | $6.93M |
| Operating income | -$27.57M | -$19.85M |
| Net income | -$26.44M | -$19.00M |
| EPS (basic) | -1.32 | -1.11 |
| EPS (diluted) | -1.32 | -1.11 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 21.81M | 17.11M |
| Balance sheet | ||
| Cash & equivalents | $31.63M | $18.53M |
| Current assets | $31.71M | $18.61M |
| Total assets | $31.71M | $18.61M |
| Current liabilities | $13.30M | $8.89M |
| Total liabilities | $13.30M | $8.89M |
| Shareholders' equity | $18.41M | $9.71M |
| Shares outstanding | 25.68M | 19.50M |
| Cash flow statement | ||
| Operating cash flow | -$16.01M | -$12.25M |
| Investing cash flow | — | $0 |
| Financing cash flow | $29.11M | $11.65M |
| Stock-based compensation | $6.03M | $4.86M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.